4,6-二氯-2-环丙基-5-硝基嘧啶 | 75438-78-7

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 4,6-二氯-2-环丙基-5-硝基嘧啶
• 英文名称: 4,6-dichloro-2-cyclopropyl-5-nitropyrimidine
• 英文别名: 2-cyclopropyl-4,6-dichloro-5-nitro-pyrimidine
• CAS: 75438-78-7
• 化学式: C₇H₅Cl₂N₃O₂
• 分子量: 234.042
• InChiKey: XCAAKLMJGXTCMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  71.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4,6-二氯-2-环丙基-5-硝基嘧啶 生成 6-(1-azepanyl)-N,2-dicyclopropyl-5-nitro-4-pyrimidinamine
  参考文献：
  名称：

  First dual M3 antagonists-PDE4 inhibitors: Synthesis and SAR of 4,6-diaminopyrimidine derivatives

  摘要：

  SAR around 4,6-diaminopyrimidine derivatives allowed the discovery of the first potent dual M-3 antagonists and PDE4 inhibitors. Various chemical modulations around that scaffold led to the discovery of ucb-101333-3 which is characterized by the most interesting profile on both targets. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.006
• 作为产物：
  描述：

  2-环丙基-6-羟基-4-(1H)-嘧啶酮 在 硝酸 、 溶剂黄146 、 N,N-二甲基苯胺 、 三氯氧磷 作用下， 生成 4,6-二氯-2-环丙基-5-硝基嘧啶
  参考文献：
  名称：

  [EN] SUBSTITUTED TRIAZOLOPYRIMIDINES AS PDE8 INHIBITORS
  [FR] TRIAZOLOPYRIMIDINES SUBSTITUÉES COMME INHIBITEURS DE PDE8

  摘要：

  式(I)的化合物：其中R1，R2，R3，R4和R5如本文所定义，已被披露。

  公开号：

  WO2011058478A1

文献信息

• Substituted aminopyrimidines
  申请人：Beiersdorf Aktiengesellschaft

  公开号：US04323570A1

  公开（公告）日：1982-04-06

  The present invention is directed to certain aminopyrimidines of the general formula ##STR1## wherein R.sup.1, R.sup.2, and R.sup.3 are hydrogen, halogen, alkoxy, alkylthio, or alkyl having 1 to 4 carbon atoms, or cycloalkyl having 3 to 5 carbon atoms and R.sup.4 is hydrogen or an aliphatic or aromatic acyl group, as well as physiologically compatible acid addition salts thereof. Compounds of the present invention are useful as blood pressure lowering agents and in the treatment of glaucoma.

  本发明涉及一些氨基嘧啶，其一般式为##STR1##其中R.sup.1、R.sup.2和R.sup.3为氢、卤素、烷氧基、烷基硫基或具有1至4个碳原子的烷基，或具有3至5个碳原子的环烷基，R.sup.4为氢或脂肪族或芳香族酰基，以及其生理兼容性酸盐。本发明的化合物可用作降血压剂和青光眼治疗。
• [EN] SUBSTITUTED TRIAZOLOPYRIMIDINES AS PDE8 INHIBITORS<br/>[FR] TRIAZOLOPYRIMIDINES SUBSTITUÉES COMME INHIBITEURS DE PDE8
  申请人：PFIZER

  公开号：WO2011058478A1

  公开（公告）日：2011-05-19

  Compounds of Formula (I): wherein R1 , R2, R3, R4, and R5 are as defined herein, are disclosed.

  式(I)的化合物：其中R1，R2，R3，R4和R5如本文所定义，已被披露。
• US4323570A
  申请人：——

  公开号：US4323570A

  公开（公告）日：1982-04-06
• First dual M3 antagonists-PDE4 inhibitors: Synthesis and SAR of 4,6-diaminopyrimidine derivatives
  作者：Laurent Provins、Bernard Christophe、Pierre Danhaive、Jacques Dulieu、Véronique Durieu、Michel Gillard、Florence Lebon、Sébastien Lengelé、Luc Quéré、BerendJan van Keulen

  DOI：10.1016/j.bmcl.2006.01.006

  日期：2006.4

  SAR around 4,6-diaminopyrimidine derivatives allowed the discovery of the first potent dual M-3 antagonists and PDE4 inhibitors. Various chemical modulations around that scaffold led to the discovery of ucb-101333-3 which is characterized by the most interesting profile on both targets. (C) 2006 Elsevier Ltd. All rights reserved.
• Discovery of triazolopyrimidine-based PDE8B inhibitors: Exceptionally ligand-efficient and lipophilic ligand-efficient compounds for the treatment of diabetes
  作者：Michael P. DeNinno、Stephen W. Wright、John B. Etienne、Thanh V. Olson、Benjamin N. Rocke、Jeffrey W. Corbett、Daniel W. Kung、Kenneth J. DiRico、Kim M. Andrews、Michele L. Millham、Janice C. Parker、William Esler、Maria van Volkenburg、David D. Boyer、Karen L. Houseknecht、Shawn D. Doran

  DOI：10.1016/j.bmcl.2012.06.079

  日期：2012.9

  PDE8B is a cAMP-specific isoform of the broader class of phosphodiesterases (PDEs). As no selective PDE8B inhibitors had been reported, a high throughput screen was run with the goal of identifying selective tools for exploring the potential therapeutic utility of PDE8B inhibition. Of the numerous hits, one was particularly attractive since it was amenable to rapid deconstruction leading to inhibitors with very high ligand efficiency (LE) and lipophilic ligand efficiency (LLE). These triazolopyrimidines were optimized for potency, selectivity and ADME properties ultimately leading to compound 42. This compound was highly potent and selective with good bioavailability and advanced into pre-clinical development. (C) 2012 Elsevier Ltd. All rights reserved.